HQ CDMO Bora health Bora Biologics
  • 中文
  • News & Events
  • Investors
  • Careers
  • Sustainable Development

Bora Pharmaceuticals

Contact
  • R & D
  • Facilities
    • Mississauga Facility
    • Zhunan Facility
    • Tainan Facility
    • Bora Biologics
  • About
  • Our Business
    • Consumer Healthcare & OTC
    • Prescription Drugs
    • Partnering

Taiwan's Leading Pharma Company

Bora expands its CMDO capabilities as it makes landmark acquisition of TWi Pharmaceuticals

Bora expands its CMDO capabilities as it makes landmark acquisition of TWi Pharmaceuticals

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market

Bora Pharmaceuticals to expand operations with $10m investment

Bora Pharmaceuticals to expand operations with $10m investment

1
2
3
Who We are

Bora Pharmaceuticals

We are focused on developing, manufacturing and selling branded, generic and over the counter (OTC) healthcare products for patients in Taiwan and around the world.

Partner IconPartner with Us

The Bora Pharmaceuticals group offers a comprehensive portfolio of expertise. We can guide you through the complex challenges of the Taiwan healthcare market.

Learn More

CDMO IconCDMO Services

We partner with leading pharmaceutical companies to enable the development, manufacture and packaging of complex modified release oral dosage drug products.

Learn More

Our Pharmaceutical Services

Contract manufacturing IconContract manufacturing

Large-scale modified release and solvent processing capabilities at state-of-the-art facilities across Taiwan.

Pharmaceutical in-licensing iconPharmaceutical in-licensing

Bora collaborates with partners to introduce its pharmaceutical products to new markets and to in-license commercial-stage or near market products.

Sales iconSales and distribution

Bora collaborates with partners to introduce its pharmaceutical products to new markets and to in-license commercial-stage or near market products.

RD Center iconR&D center

Bora's R&D laboratory has created a rich and diverse product pipeline and we share our knowledge to develop best in class products with global licensing potential.

Analytics iconAnalytics and quality control

With over 25% of its team devoted to quality, Bora can guarantee all projects are delivered to the highest-standards.

Analytics iconRegulatory record

Bora has a robust regulatory record, achieving USFDA, MHRA, Health Canada, ANVISA, EMA, PDMA, the Japanese Ministry of Health, PIC/S, TFDA, Jordan FDA, and GCC (Gulf Cooperation Council).

Targeted pharma portfolio iconTargeted pharma portfolio

We offer high-quality, affordable generic medications that help reduce healthcare costs around the world.

  • News
  • Events
Bora expands its CMDO capabilities as it makes landmark acquisition of TWi Pharmaceuticals
2022-10-03News

Bora expands its CMDO capabilities as it makes landmark acquisition of TWi Pharmaceuticals

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
2022-05-10News

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market

Bora Pharmaceuticals to expand operations with $10m investment
2022-04-20News

Bora Pharmaceuticals to expand operations with $10m investment

Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan
2021-12-09News

Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan

KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to manufacture generic product for filing in Japan
2021-08-06News

KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to manufacture generic product for filing in Japan

Bora Group announce the rebranding of Yuta Health to Bora Health
2021-07-06News

Bora Group announce the rebranding of Yuta Health to Bora Health

There are no upcoming Events at this time.

About Bora Group

Bora Pharmaceuticals and our group of companies is a publicly-traded company on the Taiwan Stock Exchange (6472). We are Taiwan's largest CDMO with a 50-year history in the Pharmaceutical Industry. We supply drugs to over 100 countries in the world, including the US/Canada, EU, Southeast Asia, Middle East, and South and Central America. We provide outsourced R&D, CDMO, and CMO services for global pharmaceutical companies around the world. 

We achieve our market leadership through dedication to the best in class:

  • QUALITY
  • TECHNICAL 
  • EXPERTISE
  • PERSONNEL

Bora Pharmaceuticals' origins began from Hoan Pharmaceuticals. Started in 1973 by John W. Sheng, it focused on in-licensing and distribution of Pharmaceuticals in Taiwan. Bora Pharmaceuticals was established in 2007 as a separate entity focused on innovative drug development and high-quality CMO/CDMO production for International markets.


Bora Graphic
  • Share

Bora Pharmaceuticals

  • Home
  • Our Business
  • R & D
  • Facilities
  • About
  • Partnering
  • News & Events
  • Investors
  • Careers

© 2023 Bora Pharmaceuticals